An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …

Purpose: To analytically and clinically validate a circulating cell-free tumor DNA sequencing
test for comprehensive tumor genotyping and demonstrate its clinical feasibility …

Next-generation sequencing (NGS) technology has expanded in the last decades with
significant improvements in the reliability, sequencing chemistry, pipeline analyses, data …

Gliomas are the most common tumours of the central nervous system and the most
aggressive form is glioblastoma (GBM). Despite advances in treatment, patient survival …

The minimally—or non-invasive detection of circulating tumor-derived components in
biofluids, such as blood, liquid biopsy is a revolutionary approach with significant potential …

Cell-free DNA (cfDNA) refers to short fragments of acellular nucleic acids detectable in
almost all body fluids, including blood, and is involved in various physiological and …

Various recent studies have focused on analyzing tumor genetic material released into the
blood stream, known as circulating tumor DNA (ctDNA). Herein, we describe current …

Purpose: The expanding number of targeted therapeutics for non–small cell lung cancer
(NSCLC) necessitates real-time tumor genotyping, yet tissue biopsies are difficult to perform …

Glioblastoma multiforme (GBM) is the most common, malignant, poorly promising primary
brain tumor. GBM is characterized by an infiltrating growth nature, abundant vascularization …